• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2016 至 2021 年英格兰地区低碳吸入器配给的时间和空间变化:一项生态学研究。

Temporal and geographical variation in low carbon inhaler dispensing in England, 2016 to 2021: an ecological study.

机构信息

School of Chemistry, University of Bristol, Bristol, BS8 1TS, UK.

Department of Life Sciences, University of Bath, Bath, BA2 7AY, UK.

出版信息

J R Soc Med. 2023 Feb;116(2):65-75. doi: 10.1177/01410768221133566. Epub 2022 Nov 16.

DOI:10.1177/01410768221133566
PMID:36382602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9944236/
Abstract

OBJECTIVES

In 2019-2020, four national recommendations were published in the United Kingdom to encourage use of low carbon inhalers. This study aimed to investigate whether these were associated with a change in primary care dispensing in England and to explore associations between geographical variation and clinical commissioning group (CCG) characteristics.

DESIGN

Ecological study using aggregated publicly available data.

SETTING

All CCGs in England (March 2016 to February 2021).

PARTICIPANTS

not applicable.

MAIN OUTCOME MEASURES

Percentage of low carbon inhalers dispensed.

RESULTS

The percentage of low carbon inhalers dispensed was 26.3% in 2020-2021 (of 8.8 million inhalers). This decreased over the study period for short-acting beta-agonist (SABA), inhaled corticosteroid (ICS) and ICS+long-acting beta-agonist (LABA) inhalers. The same trend was seen for LABA and ICS+LABA+long-acting muscarinic antagonist inhalers from 2019. The SABA and ICS classes were less often dispensed as low carbon inhalers (⁓6% versus 35-45%). Interrupted time series analyses found slight increases in low carbon inhaler percentage in the SABA, LABA and ICS classes after April 2019, which were soon erased by the long-term trend. There was also geographical variation, with the north-west, Birmingham and London consistently dispensing more low carbon inhalers. The presence of advice on climate change in CCG formularies/guidelines, the prevalence of asthma and population age profile were associated with significant variation in low carbon inhaler percentage for some classes.

CONCLUSIONS

The percentage of low carbon inhalers dispensed in England remains low and continues to decrease. Greater use of low carbon inhalers is achievable, but is more likely with locally implemented initiatives.

摘要

目的

2019-2020 年,英国发布了四项国家建议,以鼓励使用低碳吸入器。本研究旨在调查这些建议是否与英格兰初级保健配药的变化有关,并探讨地理差异与临床委托组(CCG)特征之间的关联。

设计

使用聚合的公开可用数据进行的生态研究。

地点

英格兰所有 CCG(2016 年 3 月至 2021 年 2 月)。

参与者

不适用。

主要观察指标

低碳吸入器的配药比例。

结果

2020-2021 年(880 万支吸入器)低碳吸入器的配药比例为 26.3%。在研究期间,短效β-激动剂(SABA)、吸入皮质类固醇(ICS)和 ICS+长效β-激动剂(LABA)吸入器的比例下降。2019 年也出现了 LABA 和 ICS+LABA+长效毒蕈碱拮抗剂吸入器的相同趋势。SABA 和 ICS 类别的低碳吸入器配药比例较低(⁓6%对 35-45%)。中断时间序列分析发现,2019 年 4 月后,SABA、LABA 和 ICS 类别的低碳吸入器比例略有增加,但很快被长期趋势所抹去。此外,还存在地理差异,西北部、伯明翰和伦敦一直使用更多的低碳吸入器。CCG 处方/指南中关于气候变化的建议、哮喘的流行率和人口年龄分布与某些类别的低碳吸入器比例的显著差异有关。

结论

英格兰低碳吸入器的配药比例仍然较低,且持续下降。更广泛地使用低碳吸入器是可行的,但更有可能通过地方实施的倡议来实现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2da/9944236/7f27c32debcc/10.1177_01410768221133566-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2da/9944236/d8b891a3be68/10.1177_01410768221133566-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2da/9944236/7f27c32debcc/10.1177_01410768221133566-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2da/9944236/d8b891a3be68/10.1177_01410768221133566-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2da/9944236/7f27c32debcc/10.1177_01410768221133566-fig2.jpg

相似文献

1
Temporal and geographical variation in low carbon inhaler dispensing in England, 2016 to 2021: an ecological study.2016 至 2021 年英格兰地区低碳吸入器配给的时间和空间变化:一项生态学研究。
J R Soc Med. 2023 Feb;116(2):65-75. doi: 10.1177/01410768221133566. Epub 2022 Nov 16.
2
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.不同吸入性糖皮质激素及其与长效β2受体激动剂联合使用治疗12岁及以上成人和儿童慢性哮喘比较效果的系统评价与经济学分析
Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. doi: 10.3310/hta12190.
3
Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.对于慢性阻塞性肺疾病患者,每日一次长效β₂受体激动剂/吸入性糖皮质激素联合吸入器与吸入性长效毒蕈碱拮抗剂的比较
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012355. doi: 10.1002/14651858.CD012355.pub2.
4
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.慢性阻塞性肺疾病的长效吸入疗法(β受体激动剂、抗胆碱能药物和类固醇):一项网状荟萃分析。
Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2.
5
Local variation in low carbon footprint inhalers in pre-COVID pandemic primary care prescribing guidelines for adult asthma in England and its potential impact.英国成人哮喘初级保健处方指南中 COVID-19 大流行前低碳足迹吸入器的地区差异及其潜在影响。
Br J Clin Pharmacol. 2022 Dec;88(12):5083-5092. doi: 10.1111/bcp.15511. Epub 2022 Sep 7.
6
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.双重联合疗法与长效支气管扩张剂单药治疗慢性阻塞性肺疾病(COPD)的疗效比较:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2018 Dec 3;12(12):CD012620. doi: 10.1002/14651858.CD012620.pub2.
7
Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.慢性阻塞性肺疾病加重和新使用联合维持吸入器患者的肺炎住院。
JAMA Intern Med. 2023 Jul 1;183(7):685-695. doi: 10.1001/jamainternmed.2023.1245.
8
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.不同吸入性糖皮质激素及其与长效β2受体激动剂联合使用治疗12岁以下儿童慢性哮喘的比较效果的系统评价和经济学分析
Health Technol Assess. 2008 May;12(20):1-174, iii-iv. doi: 10.3310/hta12200.
9
Symptom-driven inhaled corticosteroid/long-acting beta-agonist therapy for adult patients with asthma who are non-adherent to daily maintenance inhalers: a study protocol for a pragmatic randomized controlled trial.症状驱动的吸入性皮质类固醇/长效β-激动剂治疗对不依从每日维持吸入器的成年哮喘患者的研究方案:一项实用随机对照试验。
Trials. 2022 Dec 5;23(1):975. doi: 10.1186/s13063-022-06916-3.
10
Role of Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist Therapy in Chronic Obstructive Pulmonary Disease.长效毒蕈碱拮抗剂/长效β受体激动剂疗法在慢性阻塞性肺疾病中的作用
Ann Pharmacother. 2017 Aug;51(8):696-705. doi: 10.1177/1060028017705149. Epub 2017 Apr 14.

引用本文的文献

1
Using OpenPrescribing.net to evaluate neighbourhood-level prescribing of inhalers for asthma and COPD.使用OpenPrescribing.net评估社区层面哮喘和慢性阻塞性肺疾病吸入器的处方情况。
Sci Rep. 2025 May 24;15(1):18089. doi: 10.1038/s41598-025-02969-x.
2
Strategies and tactics to reduce the impact of healthcare on climate change: systematic review.减少医疗保健对气候变化影响的策略和方法:系统评价。
BMJ. 2024 Oct 8;387:e081284. doi: 10.1136/bmj-2024-081284.
3
Medicinal Products and Environmental Pollution.药品与环境污染

本文引用的文献

1
Investigating the prescribing trajectory and geographical drug utilisation patterns of gabapentinoids in primary care in England: An ecological study.调查英国初级保健中加巴喷丁类药物的处方轨迹和地域药物利用模式:一项生态学研究。
Br J Clin Pharmacol. 2021 Oct;87(10):4001-4012. doi: 10.1111/bcp.14827. Epub 2021 May 3.
2
Climate change in healthcare: Exploring the potential role of inhaler prescribing.医疗保健中的气候变化:探索吸入器处方的潜在作用。
Pharmacol Res Perspect. 2020 Dec;8(6):e00675. doi: 10.1002/prp2.675.
3
Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers.
Pharmaceut Med. 2024 Jan;38(1):5-7. doi: 10.1007/s40290-023-00502-x. Epub 2023 Oct 30.
4
Fixing the NHS with public health and public engagement.通过公共卫生和公众参与来修复国民医疗服务体系。
J R Soc Med. 2023 Feb;116(2):39. doi: 10.1177/01410768231154181.
将吸入疗法的环境影响降至最低:低碳吸入器政策存在的问题。
Eur Respir J. 2020 Feb 27;55(2). doi: 10.1183/13993003.00048-2020. Print 2020 Feb.
4
Carbon footprint impact of the choice of inhalers for asthma and COPD.哮喘和 COPD 患者吸入器选择的碳足迹影响。
Thorax. 2020 Jan;75(1):82-84. doi: 10.1136/thoraxjnl-2019-213744. Epub 2019 Nov 7.
5
Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England.切换至低全球变暖潜势吸入器的成本。基于英格兰国民保健服务处方数据的经济和碳足迹分析。
BMJ Open. 2019 Oct 29;9(10):e028763. doi: 10.1136/bmjopen-2018-028763.
6
Trends and variation in prescribing of low-priority treatments identified by NHS England: a cross-sectional study and interactive data tool in English primary care.英格兰国民保健制度确定的低优先级治疗方案的开具趋势和变化:英国初级医疗保健中的一项横断面研究和交互式数据工具。
J R Soc Med. 2018 Jun;111(6):203-213. doi: 10.1177/0141076818769408. Epub 2018 May 22.
7
Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.COPD 患者 GOLD A/B 初始吸入皮质类固醇使用的决定因素:英国普通实践的回顾性研究。
NPJ Prim Care Respir Med. 2017 Jun 29;27(1):43. doi: 10.1038/s41533-017-0040-z.
8
Interrupted time series regression for the evaluation of public health interventions: a tutorial.中断时间序列回归在公共卫生干预措施评价中的应用:教程。
Int J Epidemiol. 2017 Feb 1;46(1):348-355. doi: 10.1093/ije/dyw098.
9
Patient, practice and organisational influences on asthma control: observational data from a national study on primary care in the United Kingdom.患者、实践和组织因素对哮喘控制的影响:来自英国初级保健全国研究的观察性数据。
Int J Nurs Stud. 2012 May;49(5):596-609. doi: 10.1016/j.ijnurstu.2011.10.017. Epub 2011 Nov 12.
10
Retail sales of inhalation devices in European countries: so much for a global policy.欧洲国家吸入装置的零售情况:全球政策如此。
Respir Med. 2011 Jul;105(7):1099-103. doi: 10.1016/j.rmed.2011.03.012. Epub 2011 Apr 13.